LOGO
LOGO

Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Shares of Tiziana Life Sciences Ltd. (TLSA) touched a 52-week high of $1.91 last week, marking a remarkable year-to-date increase of more than 170%.This biotechnology company is focused on immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, and its lead development candidate is intranasal Foralumab, a fully human, anti-CD3 monoclonal antibody.Foralumab works by binding...

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update: May 11 – May 15, 2026

May 15, 2026 15:25 ET
Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.

Latest Updates on COVID-19